Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
114.42
+0.75 (+0.66%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
71
72
Next >
Decoding Merck & Co's Options Activity: What's the Big Picture?
August 01, 2024
Via
Benzinga
Top 3 Health Care Stocks That Are Set To Fly This Quarter
August 01, 2024
Via
Benzinga
Merck Analysts Slash Their Forecasts After Q2 Results
July 31, 2024
Via
Benzinga
Analyzing Merck & Co In Comparison To Competitors In Pharmaceuticals Industry
July 31, 2024
Via
Benzinga
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
July 31, 2024
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.
Via
InvestorPlace
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?
July 31, 2024
Find out how concerned investors should be about setbacks for this company's revolutionary new cancer therapies.
Via
The Motley Fool
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
July 29, 2024
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Merck & Co's Options: A Look at What the Big Money is Thinking
July 26, 2024
Via
Benzinga
Smart Money Is Betting Big In MRK Options
July 25, 2024
Via
Benzinga
Nasdaq Tumbles Amid Decline In Tech Stocks: Greed Index Moves To 'Fear' Zone
July 31, 2024
Market sentiment declines as Fear & Greed index moves to 'Fear' zone. Dow Jones gains ahead of major earnings and Fed policy decision.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Merck (MRK) Q2 2024 Earnings Call Transcript
July 30, 2024
MRK earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
July 30, 2024
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 30, 2024
Via
Benzinga
Merck & Co Inc. DCF Valuation: Is The Stock Undervalued?
July 19, 2024
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections.
Via
Talk Markets
Merck & Co's Options Frenzy: What You Need to Know
July 18, 2024
Via
Benzinga
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 30, 2024
Via
Benzinga
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
July 30, 2024
The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)...
Via
Benzinga
Exposures
COVID-19
Tech Stocks Drop Ahead Of Key Earnings; Nvidia Falls, CrowdStrike Hits 8-Month Low: What's Driving Markets Tuesday?
July 30, 2024
Investor sentiment took a hit on Tuesday as caution prevailed ahead of significant market events, including key tech earnings reports and the Federal Open Market Committee meeting.
Via
Benzinga
MRK Stock Earnings: Merck & Co Beats EPS, Beats Revenue for Q2 2024
July 30, 2024
MRK stock results show that Merck & Co beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
4 Stocks to Keep High on Your Buy List
July 30, 2024
Be ready for opportunities.
Via
The Motley Fool
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
July 30, 2024
Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises...
Via
Benzinga
Exposures
Product Safety
Nasdaq, S&P Futures Rise As Microsoft, AMD Earnings Take Spotlight: Will Fed Provide 'Turbo Boost' For Market? Analyst Weighs In
July 30, 2024
Wall Street is likely to tenaciously hold onto the slender optimism ahead of a slew of earnings from notable companies and the Federal Reserve’s two-day rate-setting meeting that gets underway on...
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Merck Posts Stronger-Than-Expected Results, But Outlook Falls Short
July 30, 2024
Merck reported better-than-expected earnings on Tuesday. But the pharmaceutical giant's soft outlook could pressure Merck stock.
Via
Investor's Business Daily
Earnings Divide Dow Industrials As Crux Of Q2 Season Approaches
July 25, 2024
The Dow index declined 1.3% on Wednesday, undercutting short-term support.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
July 23, 2024
Merck shares topline results from its Phase 2b/3 trial of clesrovimab, showing efficacy in reducing RSV-related infections in infants. Clesrovimab met safety and efficacy endpoints.
Via
Benzinga
Billionaires Are Loading Up on This Surging Dow Stock. Should You?
July 23, 2024
Merck stock has handily outperformed the Dow Jones Industrial Average in 2024, sparked by aggressive buying from billionaires like Citadel's Kenneth Griffin.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
July 21, 2024
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.
Via
The Motley Fool
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
July 21, 2024
This fund has a basket of growth, income, and value stocks.
Via
The Motley Fool
Topics
ETFs
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
July 19, 2024
The Nasdaq tumbled amid chip woes.
Via
Investor's Business Daily
Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits
July 18, 2024
Merck secures legal victory as 3rd U.S. Circuit Court of Appeals upholds dismissal of 1,200 lawsuits over Zostavax shingles vaccine.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
5
6
7
8
9
...
71
72
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.